Livermore David M, Mushtaq Shazad, Meunier Daniele, Hopkins Katie L, Hill Robert, Adkin Rachael, Chaudhry Aiysha, Pike Rachel, Staves Peter, Woodford Neil
Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, London, UK.
Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK.
J Antimicrob Chemother. 2017 Aug 1;72(8):2278-2289. doi: 10.1093/jac/dkx136.
We assessed the activity of ceftolozane/tazobactam against consecutive isolates collected in the BSAC Bacteraemia Surveillance from 2011 to 2015 and against 'problem' isolates sent to the UK national reference laboratory from July 2015, when routine testing began.
Susceptibility testing was by BSAC agar dilution with resistance mechanisms identified by PCR and interpretive reading.
Data were reviewed for 6080 BSAC surveillance isolates and 5473 referred organisms. Ceftolozane/tazobactam had good activity against unselected ESBL producers in the BSAC series, but activity was reduced against ertapenem-resistant ESBL producers, which were numerous among reference submissions. AmpC-derepressed Enterobacter spp. were widely resistant, but Escherichia coli with raised chromosomal AmpC frequently remained susceptible, as did Klebsiella pneumoniae with acquired DHA-1-type AmpC. Carbapenemase-producing Enterobacteriaceae were mostly resistant, except for ceftazidime-susceptible isolates with OXA-48-like enzymes. Ceftolozane/tazobactam was active against 99.8% of the BSAC Pseudomonas aeruginosa isolates; against referred P. aeruginosa it was active against 99.7% with moderately raised efflux, 94.7% with strongly raised efflux and 96.6% with derepressed AmpC. Resistance in P. aeruginosa was largely confined to isolates with metallo-β-lactamases (MBLs) or ESBLs. MICs for referred Burkholderia spp. and Stenotrophomonas maltophilia were 2-4-fold lower than those of ceftazidime.
Ceftolozane/tazobactam is active against ESBL-producing Enterobacteriaceae; gains against other problem Enterobacteriaceae groups were limited. Against P. aeruginosa it overcame the two most prevalent mechanisms (up-regulated efflux and derepressed AmpC) and was active against 51.9% of isolates non-susceptible to all other β-lactams, rising to 80.9% if ESBL and MBL producers were excluded.
我们评估了头孢洛扎/他唑巴坦对2011年至2015年英国抗菌化疗学会(BSAC)菌血症监测中收集的连续分离株以及自2015年7月常规检测开始后送至英国国家参考实验室的“问题”分离株的活性。
采用BSAC琼脂稀释法进行药敏试验,通过聚合酶链反应(PCR)和解读来确定耐药机制。
对6080株BSAC监测分离株和5473株送检菌株的数据进行了回顾。头孢洛扎/他唑巴坦对BSAC系列中未筛选的产超广谱β-内酰胺酶(ESBL)菌株具有良好活性,但对耐厄他培南的产ESBL菌株活性降低,而在送检菌株中这类菌株数量众多。AmpC去阻遏型肠杆菌属广泛耐药,但染色体AmpC升高的大肠埃希菌通常仍敏感,获得DHA-1型AmpC的肺炎克雷伯菌也是如此。产碳青霉烯酶肠杆菌科大多耐药,但对头孢他啶敏感且携带OXA-48样酶的分离株除外。头孢洛扎/他唑巴坦对99.8%的BSAC铜绿假单胞菌分离株有活性;对送检的铜绿假单胞菌,对中度升高外排的菌株活性为99.7%,对高度升高外排的菌株活性为94.7%,对去阻遏型AmpC的菌株活性为96.6%。铜绿假单胞菌的耐药主要局限于携带金属β-内酰胺酶(MBL)或ESBL的分离株。送检的伯克霍尔德菌属和嗜麦芽窄食单胞菌的最低抑菌浓度(MIC)比头孢他啶低2至4倍。
头孢洛扎/他唑巴坦对产ESBL肠杆菌科有活性;对其他问题肠杆菌科菌群的效果有限。对铜绿假单胞菌,它克服了两种最常见的耐药机制(外排上调和AmpC去阻遏),对所有其他β-内酰胺类均不敏感的分离株中有51.9%对其敏感,若排除产ESBL和产MBL菌株,这一比例升至80.9%。